OMERS ADMINISTRATION Corp Takes $5.67 Million Position in Cardinal Health, Inc. $CAH

Key Points

• OMERS Administration Corp. bought 23,861 Cardinal Health shares worth approximately $5.67 million during the second quarter. Institutional investors collectively own 87.17% of the company.
• Cardinal Health reported quarterly EPS of $2.91, beating estimates of $2.42, while revenue rose 5.8% year over year to $63.67 billion. The company issued fiscal 2027 adjusted EPS guidance of $12.40–$12.60.
• Insiders sold 210,271 shares worth about $49.6 million over the past three months, while analysts maintain a “Moderate Buy” consensus with an average price target of $266.56. The company also declared a quarterly dividend of $0.5158 per share.

OMERS ADMINISTRATION Corp purchased a new position in Cardinal Health, Inc. (NYSE:CAH - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 23,861 shares of the company's stock, valued at approximately $5,668,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CAH. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cardinal Health in the fourth quarter worth approximately $26,000. Bank of Jackson Hole Trust bought a new stake in shares of Cardinal Health during the fourth quarter valued at approximately $27,000. Jones Financial Companies Lllp increased its position in shares of Cardinal Health by 198.3% during the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock valued at $27,000 after acquiring an additional 14,034 shares in the last quarter. Palladiem LLC purchased a new position in Cardinal Health in the 4th quarter worth approximately $28,000. Finally, Indiana Trust & Investment Management Co bought a new position in Cardinal Health in the 1st quarter valued at approximately $29,000. Hedge funds and other institutional investors own 87.17% of the company's stock.

Insider Transactions at Cardinal Health

In related news, CEO Jason M. Hollar sold 80,000 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the completion of the transaction, the chief executive officer owned 235,132 shares in the company, valued at approximately $55,430,017.68. This represents a 25.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jessica L. Mayer sold 29,436 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $236.19, for a total transaction of $6,952,488.84. Following the transaction, the insider directly owned 33,076 shares of the company's stock, valued at $7,812,220.44. The trade was a 47.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 210,271 shares of company stock valued at $49,626,657. 0.12% of the stock is owned by corporate insiders.

Cardinal Health Stock Up 1.1%

Shares of CAH opened at $232.13 on Tuesday. The business has a 50-day simple moving average of $232.13 and a two-hundred day simple moving average of $217.96. The stock has a market cap of $53.99 billion, a price-to-earnings ratio of 32.11, a PEG ratio of 1.23 and a beta of 0.49. Cardinal Health, Inc. has a 52 week low of $145.87 and a 52 week high of $258.30.

Cardinal Health (NYSE:CAH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm had revenue of $63.67 billion for the quarter, compared to the consensus estimate of $65.15 billion. During the same period last year, the firm earned $2.08 EPS. The company's revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities analysts anticipate that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a $0.5158 dividend. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health's payout ratio is 28.49%.

Key Stories Impacting Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Cardinal Health’s specialty business remains a key growth driver, supporting the case for retaining CAH in portfolios. The company has also issued fiscal 2027 adjusted EPS guidance of $12.40–$12.60, broadly consistent with analyst expectations. Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
• Positive Sentiment: Recent coverage highlights Cardinal Health’s efforts to expand its healthcare reach, potentially creating additional growth opportunities beyond its core pharmaceutical distribution operations. Why Is Cardinal Health Expanding Its Healthcare Reach?
• Positive Sentiment: Cardinal Health’s latest quarterly results provided support for the stock: earnings per share exceeded consensus estimates, while revenue increased year over year. The company’s medical and pharmaceutical services also remain central to its relative performance within the healthcare providers and services group. Winners and Losers of Q2: Cardinal Health vs. Healthcare Providers and Services Stocks

Analyst Ratings Changes

Several analysts have commented on the company. UBS Group increased their target price on Cardinal Health from $274.00 to $280.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Barclays boosted their price target on Cardinal Health from $258.00 to $275.00 and gave the stock an "overweight" rating in a research note on Thursday, August 13th. Robert W. Baird increased their price objective on Cardinal Health from $251.00 to $274.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. Mizuho boosted their target price on Cardinal Health from $240.00 to $250.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Finally, TD Cowen raised their price target on shares of Cardinal Health from $275.00 to $280.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $266.56.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source